Us Bancorp \De\ Supernus Pharmaceuticals, Inc. Call Options Transaction History
Us Bancorp \De\
- $78.3 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SUPN
# of Institutions
311Shares Held
61.6MCall Options Held
11.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$429 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$256 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$198 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$125 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$114 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.21B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...